v3.26.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Operating expenses:        
Research and development $ 1,792,524 $ 1,899,251 $ 5,594,487 $ 5,291,297
General and administrative 1,655,177 1,576,577 4,951,312 5,097,694
Total operating expenses 3,447,701 3,475,828 10,545,799 10,388,991
Loss from operations (3,447,701) (3,475,828) (10,545,799) (10,388,991)
Other income (expense):        
Investment income, net 83,511 46,704 173,559 116,813
Interest expense (264,133) (341,406)
Loss on extinguishment of Note A-1 (167,643) (167,643)
Change in fair value of derivative liability 45,679 67,866
Total other (expense) income, net (302,586) 46,704 (267,624) 116,813
Net loss (3,750,287) (3,429,124) (10,813,423) (10,272,178)
Net loss available to common shareholders $ (3,813,418) $ (3,429,124) $ (10,894,606) $ (10,272,178)
Net loss per common share available to common shareholders        
Basic $ (0.64) $ (1.16) $ (2.01) $ (5.53)
Diluted $ (0.64) $ (1.16) $ (2.01) $ (5.53)
Weighted average shares outstanding        
Basic 5,947,263 2,943,655 5,408,092 1,855,922
Diluted 5,947,263 2,943,655 5,408,092 1,855,922
Series A Preferred Stock [Member]        
Other income (expense):        
Deemed Dividend - Series B Preferred Stock $ (62,331) $ (80,383)
Series B Preferred Stock [Member]        
Other income (expense):        
Deemed Dividend - Series B Preferred Stock $ (800) $ (800)